ALA Diagnostics

www.aladiagnostics.com ↗ ·Madrid ·Seed

ALA Diagnostics is a Madrid-based biotech developing in vitro diagnostic kits for neurological diseases with unmet medical need, starting with a rapid, low-cost blood test (the 'MS Kit' / 'EM Kit') for early diagnosis of Multiple Sclerosis based on a validated recombinant-protein biomarker. Founded in 2019, it is at seed/pre-market stage, has raised roughly €1.1-1.6M led by deep-science fund BeAble Capital plus Keiretsu Forum angels, and has also drawn EU (EIC/European Commission) and Spanish Ministry of Science grants totalling around €1.4M. It closed a ~€914k equity crowdfunding round on Capital Cell in December 2025 at a €5.6M pre-money valuation, opened a production laboratory in Madrid, and is running international clinical trials ahead of a planned 2026 market launch.

Founded

2019

Founders

Total funds raised

€2.4M

SectorsHealthtech & Bio, Biotech, Medical Diagnostics, Deeptech Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

José Pavía

Co-founder

José Ramón Montero

Founder & CEO / General Director

Óscar Fernández

Co-founder & Clinical Director

Global models 4

Octave Bioscience

United States · www.octavebio.com ↗

Develops and sells a blood-based multi-protein test for Multiple Sclerosis disease activity, the closest match to ALA's blood diagnostic for MS.

~$90MComparable

C2N Diagnostics

United States · www.c2n.com ↗

Sells a blood test (PrecivityAD) to diagnose a neurological disease (Alzheimer's) early, the same neuro blood-diagnostic model as ALA.

~$60MComparable

Banyan Biomarkers

United States · www.banyanbio.com ↗

Developed an FDA-cleared blood-protein biomarker test for traumatic brain injury, licensed to diagnostics makers; like ALA it turns a validated neuro biomarker into a rapid blood IVD.

~$50MComparable

ALZpath

United States · www.alzpathdx.com ↗

Sells blood-based p-tau217 assay kits and reagents for early Alzheimer's diagnosis, the same model as ALA's MS Kit: a proprietary neuro biomarker sold as a diagnostic kit.

~$15MComparable

In the same niche 48 others

See all in the Start-ups Map →

Universal Diagnostics

Venture Debt · €25.7M

Biohope

Madrid

No stage disclosed · €15M

iPremom

Valencia

Seed · €15M

+42 more →

Notes: Most funded first

Investors 3

Open as list →

BeAble Capital

beablecapital.com

Led 2 rounds · 2023–25 Spain

www.keiretsuforum.com

Investor United States

Funding rounds 3

Date	Round	Amount	Lead
2025-12-30	Seed	€0.91M	BeAble Capital +1 more
2023-10-31	Seed	€1.1M	BeAble Capital
2021-01	Pre-seed	€0.375M	Lead not disclosed

News 2

Open as list →

Published	Article
2025-10-20	ALA Diagnostics avanza en el desarrollo del primer kit diagnóstico in vitro para la esclerosis múltiple basado en un análisis de sangre ↗ iSanidad 2025-10-20
2023-10-31	BeAble Capital invierte 1 millón de euros en la empresa biotecnológica ALA Diagnostics ↗ Webcapitalriesgo 2023-10-31